Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesImpact of medical therapies on inflammatory bowel disease complication rateUse of the tumor necrosis factor-blockers for Crohn's diseaseDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabReview article: Infliximab therapy for inflammatory bowel disease--seven years onGenital and reproductive organ complications of Crohn disease: technical considerations as it relates to perianal disease, imaging features, and implications on management.Clinical value of endoluminal ultrasonography in the diagnosis of rectovaginal fistula.Uncommon acquired fistulae involving the digestive system: summary of data.Squamous Cell Carcinoma Originating from a Crohn's Enterocutaneous Fistula.Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentThe London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Efficacy and complications of surgery for Crohn's diseaseSuccessful treatment of rectovaginal fistula complicating ulcerative colitis with infliximab: a case report and review of the literature.Contemporary surgical management of rectovaginal fistula in Crohn's disease.Patient-reported outcome measures in inflammatory bowel disease.Current treatment of rectovaginal fistula in Crohn's diseaseDetection of a fluorescent-labeled avidin-nucleic acid nanoassembly by confocal laser endomicroscopy in the microvasculature of chronically inflamed intestinal mucosa.Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.Laparoscopic fistula excision and omentoplasty for high rectovaginal fistulas: a prospective study of 40 patients.Laparoscopic repair of iatrogenic vesicovaginal and rectovaginal fistula.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseDifferentiated surgical treatment of rectovaginal fistulaeClinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel diseaseToxicity of infliximab in the course of treatment of Crohn's disease.Review article: biological drugs in Crohn's disease.Inflammatory bowel disease: Pandora's box, present and future.Review article: Medical therapy for fistulizing Crohn's disease.Urogenital complications of Crohn's disease.Successful treatment of rectovaginal fistula and rectal stenosis due to perianal Crohn's disease by dual-port laparoscopic abdominoperineal resection: a report of two cases.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Therapeutic options in acute severe ulcerative colitis.Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity.How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.Perianal fistulae in Crohn's Disease: current and future approaches to treatment.Second Korean guidelines for the management of Crohn's disease.
P2860
Q22242050-8C4A0DFB-54D4-4C63-B60F-8395397A13B7Q24630083-036D4067-DC43-4F1F-B70C-53ED7C70C1A9Q26991673-FCA84011-5BE6-401F-9FD5-88BE03D8E6B2Q26995479-60E0CB58-D7F0-4C23-A00F-5AF56E29941FQ27030762-2D9F949E-BFE1-4305-B2F7-E5EE57C8D8FBQ28083872-E53EA65E-0DA9-4626-AF45-A1D5845C69D8Q28294134-72E834AA-5DCD-4B71-8016-FAA0CE5D48B2Q30238474-EDAACEAF-B142-422A-98E9-B2366D06BEB6Q30386202-16C38948-67A1-4BE5-AB33-CA285E2EF835Q31040283-48A72F9F-BAD8-42BF-B104-9E2F0248A384Q33592901-73DF9729-E09B-4220-966B-5534AF80ED99Q33646476-4DBD5094-B48B-469A-80AA-299F823CE394Q33756929-F7BF6088-42BD-4DE8-A909-3B6FF35F9CCBQ34073191-2E510CD5-D22F-4459-BB32-F37DF4CEBED6Q34147687-E151ED28-A26C-4AB6-9C2A-06565549EC3FQ34152778-35F38E06-88FD-429B-B007-7E55E6089F61Q34293341-B2FE4290-440A-4E0D-9F9D-4246428E1C6FQ34443916-9ABF9F7F-32F9-4AD4-A5E6-F3945CB616F2Q34508867-F6DA1060-1BC4-4383-AA99-4FADADA4A8A8Q34524596-762C3B0D-4064-4CDE-892F-AC90EE81672CQ34670967-C6970F85-9290-4B84-9C16-503109CD374DQ34960433-3465D009-8D6E-4DFB-94C1-E1DE286275C0Q35026410-AD2639E2-72AE-4A1C-987C-320B2E00D8BCQ35402559-43EF6834-9237-4CC2-9361-42C6E3092E02Q35480377-0B50EC80-3A34-4E32-BD6A-2EF51A45CBC2Q35559305-27BD4C56-9DF5-42A0-97B7-3EF59E0081EAQ36091579-5D06B638-82D9-433A-A147-7BDF37C23512Q36330198-4714A660-1991-444D-A42D-2E71820BEE8DQ36349717-8FBCECF0-B6C9-4C08-9149-6F22A893B9A2Q36589442-3A14BE9C-0819-46B6-B912-751E788919F2Q36631518-3E001BD1-74FE-4B92-807C-41C65DE8B97EQ36632311-29344423-ED18-4713-8B0C-5FB699B0A840Q36687469-E52A8B27-59AC-4692-B7E0-5C2F3FC174B4Q37212155-50C25CF4-2E0D-4EE8-A5CF-2ABB44AB2BBCQ37223169-36167535-5940-4A26-A4E1-D2EBDEA6AA83Q37345935-B9E1E7F4-2866-4BAC-81E9-98BA02ABA6B6Q37398298-073D19F0-B895-4A08-A3BC-94D3CCD2C7DAQ37578507-3021D1DA-BB7A-437F-91F8-B8136F591FBCQ37616110-6A2E8EBB-A272-45DA-A316-320787A1E60EQ37662498-AD30BD7C-EAF0-4185-8C3D-9386B773C630
P2860
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@en
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@nl
type
label
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@en
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@nl
prefLabel
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@en
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@nl
P2093
P1476
Long-term treatment of rectova ...... iximab in the ACCENT II Study.
@en
P2093
ACCENT II Study
Bruce E Sands
Marion A Blank
Sander J van Deventer
P304
P356
10.1016/S1542-3565(04)00414-8
P407
P577
2004-10-01T00:00:00Z